{
    "pmcid": "10886287",
    "qa_pairs": {
        "How does the paper suggest enhancing the prediction and design of nanobody binders beyond sequence data?": [
            "By integrating structural information.",
            "By increasing the size of the training dataset.",
            "By using more powerful computational hardware.",
            "By collaborating with pharmaceutical companies."
        ],
        "What challenge does the paper acknowledge in using DL models like ESM for antibody design?": [
            "The scarcity of SARS-CoV-2-specific datasets.",
            "The high computational cost of running DL models.",
            "The lack of interest from the scientific community.",
            "The difficulty in obtaining regulatory approval for AI-designed antibodies."
        ],
        "What is the primary focus of the paper regarding the use of artificial intelligence in protein therapeutics?": [
            "The use of AI in antibody design and development.",
            "The application of AI in drug delivery systems.",
            "The role of AI in vaccine development.",
            "The use of AI in protein folding prediction."
        ],
        "What is the role of ESM-1b in the context of SARS-CoV-2 antibody design?": [
            "It aids in ML-guided Antigenic Evolution Prediction (MLAEP) for developing binders against virus variants.",
            "It predicts the 3D structure of SARS-CoV-2 proteins.",
            "It sequences the entire genome of SARS-CoV-2.",
            "It identifies potential drug targets within the SARS-CoV-2 genome."
        ],
        "Which model is specifically noted for its ability to predict and generate diverse antibody sequences while maintaining structural integrity?": [
            "ESM (Evolutionary Scale Modeling)",
            "GPT-3",
            "AlphaFold",
            "BERT"
        ]
    }
}